These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25593198)

  • 1. The TLR7 agonist induces tumor regression both by promoting CD4⁺T cells proliferation and by reversing T regulatory cell-mediated suppression via dendritic cells.
    Wang C; Zhou Q; Wang X; Wu X; Chen X; Li J; Zhu Z; Liu B; Su L
    Oncotarget; 2015 Jan; 6(3):1779-89. PubMed ID: 25593198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signaling through TLR7 enhances the immunosuppressive activity of murine CD4+CD25+ T regulatory cells.
    Forward NA; Furlong SJ; Yang Y; Lin TJ; Hoskin DW
    J Leukoc Biol; 2010 Jan; 87(1):117-25. PubMed ID: 19843574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells.
    Narusawa M; Inoue H; Sakamoto C; Matsumura Y; Takahashi A; Inoue T; Watanabe A; Miyamoto S; Miura Y; Hijikata Y; Tanaka Y; Inoue M; Takayama K; Okazaki T; Hasegawa M; Nakanishi Y; Tani K
    Cancer Immunol Res; 2014 Jun; 2(6):568-80. PubMed ID: 24830413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells.
    Kurooka M; Kaneda Y
    Cancer Res; 2007 Jan; 67(1):227-36. PubMed ID: 17210703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of dendritic cells via TLR7 reduces Foxp3 expression and suppressive function in induced Tregs.
    Hackl D; Loschko J; Sparwasser T; Reindl W; Krug AB
    Eur J Immunol; 2011 May; 41(5):1334-43. PubMed ID: 21469103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cells engineered to express GITRL enhance therapeutic immunity in murine Lewis lung carcinoma.
    Ma J; Wang S; Ma B; Mao C; Tong J; Yang M; Wu C; Jiao Z; Lu L; Xu H
    Cancer Lett; 2011 Feb; 301(2):142-50. PubMed ID: 21186078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
    Hamm S; Rath S; Michel S; Baumgartner R
    J Immunotoxicol; 2009 Dec; 6(4):257-65. PubMed ID: 19848448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anticancer immunotherapy using inactivated Sendai virus particles].
    Kurooka M; Kaneda Y
    Uirusu; 2007 Jun; 57(1):19-27. PubMed ID: 18040151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity.
    Machlenkin A; Goldberger O; Tirosh B; Paz A; Volovitz I; Bar-Haim E; Lee SH; Vadai E; Tzehoval E; Eisenbach L
    Clin Cancer Res; 2005 Jul; 11(13):4955-61. PubMed ID: 16000595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
    Kikuchi T; Miyazawa N; Moore MA; Crystal RG
    Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance.
    Bourquin C; Hotz C; Noerenberg D; Voelkl A; Heidegger S; Roetzer LC; Storch B; Sandholzer N; Wurzenberger C; Anz D; Endres S
    Cancer Res; 2011 Aug; 71(15):5123-33. PubMed ID: 21697281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of toll-like receptor-7 exacerbates lupus nephritis by modulating regulatory T cells.
    Gong L; Wang Y; Zhou L; Bai X; Wu S; Zhu F; Zhu YF
    Am J Nephrol; 2014; 40(4):325-44. PubMed ID: 25341693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Up-regulation of GITRL on dendritic cells by WGP improves anti-tumor immunity in murine Lewis lung carcinoma.
    Tian J; Ma J; Ma K; Ma B; Tang X; Baidoo SE; Tong J; Yan J; Lu L; Xu H; Wang S
    PLoS One; 2012; 7(10):e46936. PubMed ID: 23077535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cells induce regulatory T cell proliferation through antigen-dependent and -independent interactions.
    Zou T; Caton AJ; Koretzky GA; Kambayashi T
    J Immunol; 2010 Sep; 185(5):2790-9. PubMed ID: 20686126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.
    Ozao-Choy J; Ma G; Kao J; Wang GX; Meseck M; Sung M; Schwartz M; Divino CM; Pan PY; Chen SH
    Cancer Res; 2009 Mar; 69(6):2514-22. PubMed ID: 19276342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toll-Like Receptor-7 Signaling Promotes Nonalcoholic Steatohepatitis by Inhibiting Regulatory T Cells in Mice.
    Roh YS; Kim JW; Park S; Shon C; Kim S; Eo SK; Kwon JK; Lim CW; Kim B
    Am J Pathol; 2018 Nov; 188(11):2574-2588. PubMed ID: 30125542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loxoribine, a selective Toll-like receptor 7 agonist, induces maturation of human monocyte-derived dendritic cells and stimulates their Th-1- and Th-17-polarizing capability.
    Dzopalic T; Dragicevic A; Vasilijic S; Vucevic D; Majstorovic I; Bozic B; Balint B; Colic M
    Int Immunopharmacol; 2010 Nov; 10(11):1428-33. PubMed ID: 20817120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I.
    Liu Q; Zhang C; Sun A; Zheng Y; Wang L; Cao X
    J Immunol; 2009 May; 182(10):6207-16. PubMed ID: 19414774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifaceted effects of synthetic TLR2 ligand and Legionella pneumophilia on Treg-mediated suppression of T cell activation.
    van Maren WW; Nierkens S; Toonen LW; Bolscher JM; Sutmuller RP; Adema GJ
    BMC Immunol; 2011 Mar; 12():23. PubMed ID: 21435210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer.
    Smyth MJ; Teng MW; Swann J; Kyparissoudis K; Godfrey DI; Hayakawa Y
    J Immunol; 2006 Feb; 176(3):1582-7. PubMed ID: 16424187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.